CRE RESPOND

CRE RESPOND is a $2.5 million multi-institutional collaborative funded by the National Health and Medical Research Council of Australia from 2021 – 2026 to reduce the burden of antimicrobial resistance through optimal personalised dosing. It aims to bring about new findings from research and share these with clinicians so that they can provide better treatment to their patients and improve outcomes for them and their families. Infection causes unacceptably high morbidity and mortality worldwide. It is common for Australian clinicians to be confronted by patients who are infected by pathogens that are resistant to all available antimicrobials. CRE RESPOND will address antimicrobial resistance and unacceptably poor patient outcomes with evidence-based personalised antimicrobial drug dosing. The CRE will achieve this through a large body of work to generate new knowledge that will change policy and practice to improve patient and health system outcomes and build research capacity to make further gains in personalizing dosing and reducing antimicrobial resistance. CRE RESPOND aims to: -Generate new knowledge that leads to improved health outcomes -Promote effective transfer of research outcomes into health policy and/or practice -Develop the health and medical research workforce by providing opportunities to advance the training of new researchers, particularly those with a capacity for independent research and future leadership roles -Facilitate collaboration